Key result
Dystrophin restoration or increased expression can serve as a pharmacodynamic biomarker to confirm the mechanism of action for therapies in Duchenne muscular dystrophy clinical trials.
This review outlines the methods and challenges of using dystrophin quantification as a pharmacodynamic biomarker in clinical trials for Duchenne muscular dystrophy.
Answers are grounded in this paper and cite their sources.
May guide DMD trial biomarker selection; leaves open assay standardization and clinical validation.
Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disease with unmet medical need. The disease is caused by mutations that disrupt the open reading frame of the dystrophin protein that is required to maintain muscle fiber stability during contraction. Lacking dystrophin patients' muscle fibers are continuously damaged eventually leading to replacement of muscle tissue by fibrotic and adipose tissues and loss of muscle function. Many therapeutic approaches aiming at dystrophin restoration are in development, and some have been or are being tested in clinical trials. For these approaches, showing dystrophin restoration or increased dystrophin expression could serve as a pharmacodynamic biomarker to confirm mechanism of action. This review provides an overview of methods currently in use to assess dystrophin in clinical trial muscle biopsies and discusses challenges of dystrophin quantification and using dystrophin as a biomarker in clinical trials.
No takes yet. Share an insight, caveat, or question.
Annemieke Aartsma‐Rus (2014) conducted a review in Duchenne muscular dystrophy (DMD). Dystrophin restoration therapies was evaluated on Dystrophin restoration or increased dystrophin expression. Dystrophin restoration or increased expression can serve as a pharmacodynamic biomarker to confirm the mechanism of action for therapies in Duchenne muscular dystrophy clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: